Immunohistochemistry, FISH, and PCR-based diagnostic techniques used in modern pathology, one technique per card.
About this set
35 basic cards for USMLE Step 1 Pathology. Set 13 of 27 in USMLE Pathology. It opens with "Which IHC marker identifies epithelial cell origin in a tumor (e.g., carcinoma)?" and "Which IHC marker identifies mesenchymal cell origin (e.g., sarcoma)?". Study it alongside the other USMLE Step 1 sets below.
35 cards · basic cards · AI-written, checked twice. Edit anything.
- Which IHC marker identifies epithelial cell origin in a tumor (e.g., carcinoma)?
Show answer
Cytokeratin- Which IHC marker identifies mesenchymal cell origin (e.g., sarcoma)?
Show answer
Vimentin- Which IHC marker indicates muscle differentiation in a tumor?
Show answer
Desmin- Which IHC marker is positive in melanoma, schwannoma, and Langerhans cell histiocytosis?
Show answer
S-100- Which IHC marker identifies glial cell tumors such as astrocytoma?
Show answer
GFAP (glial fibrillary acidic protein)- Which IHC marker, also called leukocyte common antigen, marks cells of hematopoietic origin?
Show answer
CD45- Which IHC marker identifies B lymphocytes?
Show answer
CD20- Which IHC marker identifies T lymphocytes?
Show answer
CD3- Which IHC marker is characteristic of lung and thyroid adenocarcinomas?
Show answer
TTF-1 (thyroid transcription factor-1)- Which IHC marker is used to identify prostate adenocarcinoma?
Show answer
PSA (prostate-specific antigen)- Which IHC marker identifies neuroendocrine tumors such as carcinoid and small cell carcinoma?
Show answer
Chromogranin A- Which IHC marker, alongside chromogranin, confirms neuroendocrine differentiation?
Show answer
Synaptophysin- Which IHC marker is specific for melanoma?
Show answer
HMB-45- What does IHC staining for ER/PR status determine in a breast cancer specimen?
Show answer
Whether the tumor expresses estrogen and progesterone receptors, guiding hormonal therapy- What does positive HER2 IHC staining in breast cancer indicate?
Show answer
Overexpression of the HER2/neu receptor, guiding trastuzumab therapy
FlashKeepers